BG Medicine, Inc. (BGMD)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2015 | -4.63 Million USD | 37.11% |
| 2014 | -7.36 Million USD | 48.78% |
| 2013 | -14.37 Million USD | 36.76% |
| 2012 | -22.72 Million USD | -29.99% |
| 2011 | -17.48 Million USD | -19.71% |
| 2010 | -14.6 Million USD | 8.64% |
| 2009 | -15.98 Million USD | -51.19% |
| 2008 | -10.57 Million USD | 0.0% |
| 2006 | -4.19 Million USD | 45.59% |
| 2005 | -7.7 Million USD | 9.8% |
| 2004 | -8.54 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2015 FY | -4.63 Million USD | 37.11% |
| 2015 Q3 | -1.02 Million USD | 29.0% |
| 2015 Q4 | -902 Thousand USD | 12.09% |
| 2015 Q1 | -1.25 Million USD | -3.72% |
| 2015 Q2 | -1.44 Million USD | -15.05% |
| 2014 Q1 | -1.94 Million USD | -17.22% |
| 2014 FY | -7.36 Million USD | 48.78% |
| 2014 Q3 | -2.23 Million USD | -13.29% |
| 2014 Q4 | -1.21 Million USD | 45.77% |
| 2014 Q2 | -1.97 Million USD | -1.23% |
| 2013 Q3 | -3.36 Million USD | 26.07% |
| 2013 FY | -14.37 Million USD | 36.76% |
| 2013 Q2 | -4.54 Million USD | 5.25% |
| 2013 Q1 | -4.8 Million USD | -84.3% |
| 2013 Q4 | -1.66 Million USD | 50.61% |
| 2012 Q3 | -6.53 Million USD | -7.38% |
| 2012 Q2 | -6.08 Million USD | 18.84% |
| 2012 Q1 | -7.5 Million USD | -58.39% |
| 2012 FY | -22.72 Million USD | -29.99% |
| 2012 Q4 | -2.6 Million USD | 60.14% |
| 2011 Q4 | -4.73 Million USD | 3.62% |
| 2011 Q1 | -2.99 Million USD | -8.71% |
| 2011 Q2 | -4.84 Million USD | -61.58% |
| 2011 FY | -17.48 Million USD | -19.71% |
| 2011 Q3 | -4.91 Million USD | -1.49% |
| 2010 Q4 | -2.75 Million USD | 22.54% |
| 2010 FY | -14.6 Million USD | 8.64% |
| 2010 Q3 | -3.55 Million USD | -0.71% |
| 2010 Q2 | -3.53 Million USD | 25.76% |
| 2010 Q1 | -4.75 Million USD | -14.4% |
| 2009 Q4 | -4.16 Million USD | 4.61% |
| 2009 FY | -15.98 Million USD | -51.19% |
| 2009 Q3 | -4.36 Million USD | 0.0% |
| 2008 FY | -10.57 Million USD | 0.0% |
| 2007 Q3 | -2.18 Million USD | -7.39% |
| 2007 Q2 | -2.03 Million USD | -32.51% |
| 2007 Q1 | -1.53 Million USD | -10313.33% |
| 2006 FY | -4.19 Million USD | 45.59% |
| 2006 Q3 | -1.14 Million USD | -5.9% |
| 2006 Q1 | -1.97 Million USD | 0.0% |
| 2006 Q2 | -1.08 Million USD | 45.11% |
| 2006 Q4 | 15 Thousand USD | 101.31% |
| 2005 FY | -7.7 Million USD | 9.8% |
| 2004 FY | -8.54 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.16 Million USD | 100.0% |
| Ansell Limited | 129.3 Million USD | 100.0% |
| Ansell Limited | 129.3 Million USD | 100.0% |
| Biotage AB (publ) | 31.13 Million USD | 100.0% |
| BioLife Sciences Inc. | - USD | NaN% |
| CB Scientific, Inc. | -1.59 Million USD | 100.0% |
| Psykey, Inc. | -797.5 Thousand USD | 100.0% |
| ConvaTec Group Plc | 262.7 Million USD | 100.0% |
| ConvaTec Group Plc | 262.7 Million USD | 100.0% |
| Encision Inc. | -640.78 Thousand USD | 100.0% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 100.0% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 100.0% |
| Innovative MedTech Inc. | -4.27 Million USD | 100.0% |
| LifePoint, Inc. | -7.49 Million USD | 100.0% |
| Medite Cancer Diagnostics, Inc. | -6.48 Million USD | 100.0% |
| Paradigm Medical Industries, Inc. | 330 Thousand USD | 100.0% |
| QuantRx Biomedical Corporation | - USD | NaN% |
| Remedent, Inc. | -122.89 Thousand USD | 100.0% |
| Reflect Scientific, Inc. | -467.27 Thousand USD | 100.0% |
| SmileDirectClub, Inc. | -241.15 Million USD | 100.0% |
| Sector 10, Inc. | -39.84 Thousand USD | 100.0% |
| Shandong Weigao Group Medical Polymer Company Limited | 319.6 Million USD | 100.0% |
| SheerVision, Inc. | 155.72 Thousand USD | 100.0% |
| United Health Products, Inc. | -2.42 Million USD | 100.0% |
| Vasamed, Inc. | 4.74 Million USD | 100.0% |
| Wearable Health Solutions, Inc. | -2.29 Million USD | 100.0% |
| Yubo International Biotech Limited | -1.2 Million USD | 100.0% |